Table 1 The relationship between expression of YAP and clinical pathological features in pancreatic cancer
Samples (n) | YAP expression n (%) | |||||
|---|---|---|---|---|---|---|
None | Weak | Moderate | Strong | P valueâ—Š | ||
Sex | 0.755 | |||||
 Male | 45 | 8(17.8) | 19(42.2) | 9(20.0) | 9(20.0) | |
 Female | 27 | 6(22.2) | 8(29.6) | 6(22.2) | 7(26.0) | |
Age | 0.306 | |||||
 ≤55a | 37 | 9(24.3) | 16(43.2) | 6(16.2) | 6(16.2) | |
 >55 | 35 | 5(14.3) | 11(31.4) | 9(25.7) | 10(28.6) | |
Histological grade | 0.780 | |||||
 Well | 11 | 2(18.2) | 6(54.5) | 1(9.1) | 2(18.2) | |
 Moderate | 49 | 11(22.4) | 16(32.7) | 11(22.4) | 11(22.4) | |
 Poor | 12 | 1(8.3) | 5(41.7) | 3(25.0) | 3(25.0) | |
TNM stage (AJCC) | 0.012* | |||||
 I | 2 | 1(50.0) | 1(50.0) | 0(0) | 0(0) | |
 II | 59 | 12(20.3) | 26(44.1) | 9(15.3) | 12(20.3) | |
 III | 6 | 1(16.7) | 0(0) | 4(66.7) | 1(16.7) | |
 IV | 5 | 0(0) | 0(0) | 2(40.0) | 3(60.0) | |
pT status | 0.135 | |||||
 T1 | 0 | 0(0) | 0(0) | 0(0) | 0(0) | |
 T2 | 8 | 1(12.5) | 3(37.5) | 2(25) | 2(25) | |
 T3 | 58 | 12(20.7) | 24(41.4) | 9(15.5) | 13(22.4) | |
 T4 | 6 | 1(16.7) | 0(0) | 4(66.7) | 1(16.7) | |
pN status | 0.755 | |||||
 N0 | 55 | 11(20.0) | 22(40.0) | 10(18.2) | 12(21.8) | |
 N1 | 17 | 3(17.7) | 5(29.4) | 5(29.4) | 4(23.5) | |
pM status | 0.028* | |||||
 M0 | 67 | 14(20.9) | 27(40.3) | 13(19.4) | 13(19.4) | |
 M1 | 5 | 0(0) | 0(0) | 2(40.0) | 3(60.0) | |